238756-65-5

Upstream product

• 170104-96-8 5,8-Dibromo-2-bromomethyl-7,10-dihydroxy-6H-pyrazolo<4,5,1-de>acridin-6-one 
• 170104-98-0 5,8-Dibromo-2-bromomethyl-6H-pyrazolo<4,5,1-de>acridine-6,7,10-trione 
• 170105-03-0 5,8-Dibromo-2-bromomethyl-7-hydroxy-6H-pyrazolo<4,5,1-de>acridin-6-one 
• 238756-61-1 Methyl 2-(6-bromo-3-bromomethyl-1H-indazol-1-yl)-6-methoxybenzoate 
• 238756-60-0 Methyl 2-(6-bromo-3-methyl-1H-indazol-1-yl)-6-methoxybenzoate 
• 126955-38-2 5-bromo-2-(bromomethyl)-7-hydroxy-6H-pyrazolo<4,5,1-de>acridin-6-one 
• 109-76-2 Trimethylenediamine 
• 170104-99-1 2-<<(1-Benzyl-2-hydroxyethyl)amino>methyl>-5,8-dibromo-7,10-dihydroxy-6H-pyrazolo<4,5,1-de>acridin-6-one 

Relevant academic research and scientific papers

An efficient synthesis of a new class of DNA intercalating antitumor 7,10-dihydroxy-6H-pyrazolo[4,5,1-de]acridin-6-ones

An efficient synthesis of KW-2170 (1), which is a 7,10-dihydroxy-6H- pyrazolo[4,5,1-de]acridin-6-one derivative and a new class of DNA intercalating antitumor agents, is described. The selective monobromination of the methyl group before the cyclization to the pyrazoloacridone is easily carried out. In the improved process, the bromination of the corresponding methyl group is achieved prior to the hydroquinone formation, so the protection of the hydroxy groups is not necessary unlike the original method. In comparison with the original synthetic route of KW-2170 (1), the new route decreases the synthetic steps from 2-bromo-6-methoxybenzoic acid (2) from 15 to 13 and increases the overall yield from 2 to 12%.